Compounds > 14-iodo-15-hydroxyeicosatrienoic-acid--omega-lactone

14-iodo-15-hydroxyeicosatrienoic-acid--omega-lactone and Goiter

14-iodo-15-hydroxyeicosatrienoic-acid--omega-lactone has been researched along with Goiter* in 2 studies

Other Studies

2 other study(ies) available for 14-iodo-15-hydroxyeicosatrienoic-acid--omega-lactone and Goiter

Article	Year
Studies on the goiter inhibiting action of iodolactones. European journal of pharmacology, 1994, Jun-02, Volume: 258, Issue:1-2 The thyroid gland synthesizes 6-delta-iodolactone, a compound shown to inhibit goiter growth in vivo and cell proliferation in culture. The present studies were performed to characterize this effect further with the aim of exploring the possible therapeutic action of iodolactones. Prevention assay: rats were treated simultaneously with a goitrogen, methylmercaptoimidazole, and either 6-delta-iodo-lactone or 14-iodo-omega-lactone, a synthetic derivative, given either i.p. or p. o. Both compounds caused a significant decrease in thyroid weight irrespective of the route of administration, but oral administration was less effective. A dose-response relationship was observed, the minimal effective dose (i.p.) being 3 micrograms/day. Involution assay: goiter was first induced with methylmercaptoimidazole and then the iodolactones were injected. Both compounds caused a significant involution, which was dose-related. Acute (10 days) administration of the iodolactones did not produce significant changes in several serum parameters (total T3 and T4, cholesterol, total protein, urea and acetylcholinesterase). These results give further support to the potential therapeutic application of iodolactones. Topics: Administration, Oral; Animals; Arachidonic Acids; Cells, Cultured; Dose-Response Relationship, Drug; Female; Goiter; Hydroxyeicosatetraenoic Acids; Injections, Intraperitoneal; Methimazole; Rats; Rats, Wistar; Thyroid Gland	1994
Further studies on the antigoitrogenic action of iodoarachidonates. Thyroidology, 1992, Volume: 4, Issue:1 Previous studies have shown that iodoarachidonates (IAs) prevent goiter production in rats. In the present studies we show that both IL-d and IL-w (IAs bearing the iodine atom at the positions 6 and 14, respectively), cause a significant involution of preformed goiter. This effect was evident when IAs were administered either orally or via i.p., although the first one required larger doses to obtain the same degree of inhibition. No changes were observed in serum protein, urea, cholesterol, cholinesterase, T3 or T4. In vitro studies with FRTL-5 cells showed that both IAs inhibit iodide and alpha-AIB uptake, as well as ATPase activity. Topics: Adenosine Triphosphatases; Administration, Oral; Animals; Arachidonic Acids; Cells, Cultured; Deoxyglucose; Goiter; Hydroxyeicosatetraenoic Acids; Injections, Intraperitoneal; Iodides; Methimazole; Rats; Thyroid Gland	1992

Article

Year

Studies on the goiter inhibiting action of iodolactones.

European journal of pharmacology, 1994, Jun-02, Volume: 258, Issue:1-2

The thyroid gland synthesizes 6-delta-iodolactone, a compound shown to inhibit goiter growth in vivo and cell proliferation in culture. The present studies were performed to characterize this effect further with the aim of exploring the possible therapeutic action of iodolactones. Prevention assay: rats were treated simultaneously with a goitrogen, methylmercaptoimidazole, and either 6-delta-iodo-lactone or 14-iodo-omega-lactone, a synthetic derivative, given either i.p. or p. o. Both compounds caused a significant decrease in thyroid weight irrespective of the route of administration, but oral administration was less effective. A dose-response relationship was observed, the minimal effective dose (i.p.) being 3 micrograms/day. Involution assay: goiter was first induced with methylmercaptoimidazole and then the iodolactones were injected. Both compounds caused a significant involution, which was dose-related. Acute (10 days) administration of the iodolactones did not produce significant changes in several serum parameters (total T3 and T4, cholesterol, total protein, urea and acetylcholinesterase). These results give further support to the potential therapeutic application of iodolactones.

Topics: Administration, Oral; Animals; Arachidonic Acids; Cells, Cultured; Dose-Response Relationship, Drug; Female; Goiter; Hydroxyeicosatetraenoic Acids; Injections, Intraperitoneal; Methimazole; Rats; Rats, Wistar; Thyroid Gland

1994

Further studies on the antigoitrogenic action of iodoarachidonates.

Thyroidology, 1992, Volume: 4, Issue:1

Previous studies have shown that iodoarachidonates (IAs) prevent goiter production in rats. In the present studies we show that both IL-d and IL-w (IAs bearing the iodine atom at the positions 6 and 14, respectively), cause a significant involution of preformed goiter. This effect was evident when IAs were administered either orally or via i.p., although the first one required larger doses to obtain the same degree of inhibition. No changes were observed in serum protein, urea, cholesterol, cholinesterase, T3 or T4. In vitro studies with FRTL-5 cells showed that both IAs inhibit iodide and alpha-AIB uptake, as well as ATPase activity.

Topics: Adenosine Triphosphatases; Administration, Oral; Animals; Arachidonic Acids; Cells, Cultured; Deoxyglucose; Goiter; Hydroxyeicosatetraenoic Acids; Injections, Intraperitoneal; Iodides; Methimazole; Rats; Thyroid Gland

1992